Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

5.73
+0.41007.71%
Pre-market: 5.67-0.0579-1.01%07:22 EDT
Volume:623.88K
Turnover:3.53M
Market Cap:456.35M
PE:-7.56
High:5.90
Open:5.39
Low:5.39
Close:5.32
52wk High:5.90
52wk Low:0.8129
Shares:79.64M
Float Shares:50.90M
Volume Ratio:2.10
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7580
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:3.41
PE(LYR):-4.43

Loading ...

Prelude Therapeutics Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Yesterday

Cardiff Oncology Q2 Operating Expenses Fall on Lower R&D Costs

Reuters
·
Yesterday

Bolt Biotherapeutics Q2 Net Loss Narrows on Restructuring and Lower Research Activity

Reuters
·
Yesterday

Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M

Benzinga Earnings
·
Aug 11

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

TIPRANKS
·
Aug 11

Prelude Therapeutics Q2 Revenue USD 5.704 Million

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Prelude Therapeutics Incorporated Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Prelude Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga Earnings
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12